SEARCH
= Paid-up subscribersIncretin-based diabetes therapy not associated with increased mortality
Incretin-based diabetes therapy not associated with increased mortality
28 Jul 2017
A recent meta-analysis, published in the BMJ, has shown no increase in all cause mortality in patients with type 2 diabetes using incretin-based treatments i.e. GLP-1 agonists and DPP-4 inhibitors.
This article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.